Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients

被引：0
|
作者：
Daar, S.
Taher, A.
Pathare, A.
Nick, H.
Krahn, U.
Hadler, D.
机构：
[1] Sultan Qaboos Univ, Muscat, Oman
[2] Amer Univ Beirut, Beirut, Lebanon
[3] Novartis, Basel, Switzerland
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2007年 / 82卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：513 / 514
页数：2
相关论文
共 43 条
  • [1] Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients.
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    Capdeville, Renaud
    BLOOD, 2006, 108 (11) : 503A - 503A
  • [2] A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
    Cappellini, MD
    Cohen, A
    Piga, A
    Bejaoui, M
    Perrone, S
    Agaoglu, L
    Aydinok, Y
    Kattamis, A
    Kilinc, Y
    Porter, J
    Capra, M
    Galanello, R
    Fattoum, S
    Drelichman, G
    Magnano, C
    Verissimo, M
    Athanassiou-Metaxa, M
    Giardina, P
    Kourakli-Symeonidis, A
    Janka-Schaub, G
    Coates, T
    Vermylen, C
    Olivieri, N
    Thuret, I
    Opitz, H
    Ressayre-Djaffer, C
    Marks, P
    Alberti, D
    BLOOD, 2006, 107 (09) : 3455 - 3462
  • [3] Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in pediatric patients
    Piga, Antonio
    Vichinsky, Elliott
    Forni, Gian Luca
    Kilinc, Yurdanur
    Maseruka, Henry
    Kattamis, Antonios
    BLOOD, 2007, 110 (11) : 815A - 815A
  • [4] Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis
    Porter, J
    Borgna-Pignatti, C
    Baccarani, M
    Saviano, A
    Abish, S
    Malizia, R
    Nick, H
    Opitz, H
    Rabault, B
    Gathmann, I
    Marks, P
    BLOOD, 2005, 106 (11) : 755A - 756A
  • [5] The once-daily oral chelator deferasirox (exjade®, ICL670) reduces iron overload in a murine model of juvenile hemochromatosis
    Nick, Hanspeter
    Allegrini, Peter
    Fozard, Lucy
    Junker, Ursula
    Rojkjaer, Lisa
    O'Reilly, Terrence
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 555 - 555
  • [6] Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload.
    Cappellini, M. D.
    Giardina, P.
    Porter, J.
    Coates, T.
    Della Porta, M. G.
    Siegel, J.
    Glimm, E.
    Ford, J.
    Cappellini, Maria Dominica
    BLOOD, 2006, 108 (11) : 501A - 501A
  • [7] Plasma LPI in β-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670).
    Daar, S
    Taher, A
    Pathare, A
    Krahn, U
    Gathmann, I
    Nick, H
    Hadler, D
    BLOOD, 2005, 106 (11) : 758A - 758A
  • [8] Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Galanello, Renzo
    Piga, Antonio
    Williamson, Paul
    Porter, John B.
    BLOOD, 2007, 110 (11) : 816A - 816A
  • [9] Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)
    Vichinsky, Elliott
    Coates, Thomas D.
    Thompson, Alexis A.
    Mueller, Brigitta U.
    Lagrone, Darlene
    Heeney, Matthew M.
    BLOOD, 2007, 110 (11) : 995A - 995A
  • [10] Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade®) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis
    Cappellini, M
    Bejaoui, M
    Perrotta, S
    Agaoglu, L
    Kattamis, A
    Giardina, P
    Janka-Schaub, G
    Opitz, H
    Ressayre-Djaffer, C
    Alberti, D
    BLOOD, 2004, 104 (11) : 984A - 984A
12345